2022 Monkeypox Outbreak:
Global Trends

World Health Organization

Produced on 20 September 2022

logo

1 Overview

This report provides a global overview of the monkeypox epidemiological situation as reported to WHO as of September 19 2022. The report focuses on laboratory confirmed cases1 as defined by the WHO’s working case definition published in the Surveillance, case investigation and contact tracing for monkeypox interim guidance. Note that countries may use their own case definitions separate from those outlined in the above document. This report should be considered in the context of other WHO information products associated with the 2022 monkeypox outbreak, and monkeypox in general:

  • The biweekly Situation Report provides a comprehensive update of the monkeypox situation and response activities across a variety of domains such as epidemiology, clinical management and communications, replacing the previous Disease Outbreak News format;

  • The Emergency Dashboard provides the latest daily data on total cases and deaths of monkeypox, as well as other events and emergencies to which WHO is responding;

  • This global epidemiological report provides in-depth epidemiological information about the monkeypox situation, based primarily on case report forms provided by Member States to WHO under Article 6 of the International Health Regulations (IHR 2005).

Links to these products can be see in more detail at the end of the report.

Since 1 January 2022, cases of monkeypox have been reported to WHO from 105 Member States across all 6 WHO regions. As of September 19 2022 at 17h CEST, a total of 61,753 laboratory confirmed cases and 533 probable cases, including 23 deaths, have been reported to WHO. Since 13 May 2022, a high proportion of these cases have been reported from countries without previously documented monkeypox transmission. This is the first time that cases and sustained chains of transmission have been reported in countries without direct or immediate epidemiological links to areas of West or Central Africa.

With the exception of countries2 in West and Central Africa, the ongoing outbreak of monkeypox continues to primarily affect men who have sex with men who have reported recent sex with one or multiple partners. At present there is no signal suggesting sustained transmission beyond these networks.

Confirmation of one case of monkeypox, in a country, is considered an outbreak. The unexpected appearance of monkeypox in several regions in the initial absence of epidemiological links to areas in West and Central Africa, suggests that there may have been undetected transmission for some time.

WHO assesses the global risk as Moderate. Regionally, WHO assesses the risk in the European Region and the Region of the Americas as High and as Moderate in the African Region, Eastern Mediterranean Region and the South-East Asia Region. The risk in the Western Pacific Region is assessed as Low-Moderate. The IHR Emergency Committee on the multi-country outbreak of monkeypox held its second meeting on 21 July 2022. Having considered the views of committee members and advisors as well as other factors in line with the International Health Regulations (2005), the WHO Director-General declared this outbreak a public health emergency of international concern and issued temporary recommendations in relation to the outbreak.

 


  1. For the WHO European region, both confirmed and probable cases are included within confirmed case counts and detailed case data.

  2. Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory

  3. All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).


2 Global situation update

The number of weekly1 reported new cases globally has decreased by 22% in week 37 (12 Sep - 18 Sep) (n = 3,794 cases) compared to week 36 (05 Sep - 11 Sep) (n = 4,863 cases). The majority of cases reported in the past 4 weeks were notified from the Region of the Americas (80.3%) and the European Region (18.6%).

The 10 most affected countries globally are: United States of America (n = 22,957), Spain (n = 7,037), Brazil (n = 6,649), France (n = 3,898), Germany (n = 3,563), The United Kingdom (n = 3,552), Peru (n = 2,054), Canada (n = 1,363), Colombia (n = 1,260), and Netherlands (n = 1,209). Together, these countries account for 86.7% of the cases reported globally.

In the past 7 days, 23 countries reported an increase in the weekly number of cases, with the highest increase reported in Chile. 33 countries have reported no new cases in the past 21 days.

In the past 7 days, 3 countries reported their first case. countries which reported their first case in the past 7 days are: Guam (12 September), Ukraine (15 September), Bahrain (16 September).

Global data are data collected by public sources. These data are largely aggregated cases that have been reported from open and official country sources. The below epidemic curve shows the aggregated number of cases by week according to the date of case reporting.

2.1 Epidemic curve (cases)

Epidemic curve shown for cases reported up to 18 Sep 2022 to avoid showing incomplete weeks of data.

2.2 Epidemic curve (deaths)

Epidemic curve shown for deaths reported up to 18 Sep 2022 to avoid showing incomplete weeks of data.

2.3 Epidemic curve by WHO Region (cases)

Epidemic curve shown for cases reported up to 18 Sep 2022 to avoid showing incomplete weeks of data. Note different y-axis scales.

2.4 Epidemic curve by WHO Region (deaths)

Epidemic curve shown for deaths reported up to 18 Sep 2022 to avoid showing incomplete weeks of data. Note different y-axis scales.

2.5 Epidemic curve - top 10 countries (cases)

Epidemic curve shown for cases reported up to 18 Sep 2022 to avoid showing incomplete weeks of data. Note different y-axis scales.

2.6 Global Map

2.7 Table - Cases and deaths by WHO Region

Total Monkeypox cases, by WHO region
From 1 Jan 2022. Data as of 19 Sep 2022
Total Confirmed Cases Total Probable Cases Total Deaths Cases in past week1 7-day % change in cases1
Region of the Americas 36,783 533 4 3,361 −18%
European Region 24,138 0 3 407 −42%
African Region 587 0 14 11 −81%
Western Pacific Region 173 0 0 8 33%
Eastern Mediterranean Region 51 0 1 4 −50%
South-East Asia Region 21 0 1 3 100%
Total 61,753 533 23 3,794 −22%
1 Using most recently complete international standard week (Monday - Sunday)


2.8 Table - Cases and deaths by country

Total Monkeypox cases, by WHO region
From 1 Jan 2022. Data as of 19 Sep 2022
Total Confirmed Cases Total Probable Cases Total Deaths
Region of the Americas
United States of America 22,957 0 0
Brazil 6,649 423 2
Peru 2,054 0 0
Canada 1,363 101 0
Colombia 1,260 0 0
Mexico 1,049 0 0
Chile 728 2 0
Argentina 265 0 0
Puerto Rico 160 0 0
Bolivia (Plurinational State of) 129 0 0
Ecuador 68 1 1
Dominican Republic 31 1 0
Panama 12 0 0
Guatemala 12 3 0
Jamaica 12 0 0
Uruguay 5 0 0
Honduras 4 0 0
Costa Rica 4 0 0
Venezuela (Bolivarian Republic of) 3 0 0
Aruba 3 0 0
Bahamas 2 0 0
Cuba 2 0 1
Guyana 2 0 0
El Salvador 2 0 0
Barbados 1 0 0
Bermuda 1 0 0
Guadeloupe 1 0 0
Martinique 1 0 0
Paraguay 1 0 0
Saint Martin 1 0 0
Curaçao 1 2 0
European Region
Spain 7,037 0 2
France 3,898 0 0
Germany 3,563 0 0
The United Kingdom 3,552 0 0
Netherlands 1,209 0 0
Portugal 908 0 0
Italy 828 0 0
Belgium 744 0 1
Switzerland 502 0 0
Austria 301 0 0
Israel 247 0 0
Denmark 183 0 0
Sweden 179 0 0
Ireland 173 0 0
Poland 167 0 0
Norway 89 0 0
Hungary 75 0 0
Greece 69 0 0
Czechia 65 0 0
Luxembourg 55 0 0
Slovenia 46 0 0
Romania 38 0 0
Finland 33 0 0
Malta 33 0 0
Serbia 31 0 0
Croatia 27 0 0
Slovakia 14 0 0
Iceland 12 0 0
Estonia 11 0 0
Bulgaria 6 0 0
Gibraltar 6 0 0
Cyprus 5 0 0
Latvia 5 0 0
Lithuania 5 0 0
Andorra 4 0 0
Bosnia and Herzegovina 3 0 0
Monaco 3 0 0
Georgia 2 0 0
Greenland 2 0 0
Montenegro 2 0 0
Republic of Moldova 2 0 0
Russian Federation 2 0 0
Türkiye 1 0 0
Ukraine 1 0 0
African Region
Nigeria 277 0 6
Democratic Republic of the Congo 195 0 0
Ghana 84 0 4
Central African Republic 8 0 2
Cameroon 7 0 2
Congo 5 0 0
South Africa 5 0 0
Benin 3 0 0
Liberia 3 0 0
Western Pacific Region
Australia 132 0 0
Singapore 19 0 0
New Zealand 5 0 0
China1 5 0 0
Japan 4 0 0
Philippines 4 0 0
Republic of Korea 2 0 0
New Caledonia 1 0 0
Guam 1 0 0
Eastern Mediterranean Region
United Arab Emirates 16 0 0
Lebanon 11 0 0
Saudi Arabia 8 0 0
Sudan 6 0 1
Qatar 4 0 0
Morocco 3 0 0
Iran (Islamic Republic of) 1 0 0
Jordan 1 0 0
Bahrain 1 0 0
South-East Asia Region
India 12 0 1
Thailand 8 0 0
Indonesia 1 0 0
-
Total 61,753 533 23
1 Cases shown include those in mainland China, Hong Kong SAR and Taipei


2.9 Table - African Region

Summary of Monkeypox cases
As of 19 Sep 2022
Total Cases Total cases per 1M inhabitants Cases in past week1 7-day % change in cases1 Days since last report Date of first reported case
African Region
Nigeria 277 1 0 −100% 0 02 Jan 2022
Democratic Republic of the Congo 195 2 0 0% 0 13 Jun 2022
Ghana 84 3 8 0% 0 13 Jun 2022
Central African Republic 8 2 0 0% 0 13 Feb 2022
Cameroon 7 0 0 0% 0 13 Jun 2022
Congo 5 1 2 0% 0 21 May 2022
South Africa 5 0 0 0% 0 23 Jun 2022
Benin 3 0 0 0% 0 15 Jun 2022
Liberia 3 1 1 0% 0 01 Aug 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.10 Table - Region of the Americas

Summary of Monkeypox cases
As of 19 Sep 2022
Total Cases Total cases per 1M inhabitants Cases in past week1 7-day % change in cases1 Days since last report Date of first reported case
Region of the Americas
United States of America 22,957 69 1453 −60% 2 03 Jun 2022
Brazil 6,649 31 678 −53% 2 10 Jun 2022
Peru 2,054 62 246 −52% 2 28 Jun 2022
Canada 1,363 36 42 −43% 2 03 Jun 2022
Colombia 1,260 25 322 −53% 5 25 Jun 2022
Mexico 1,049 8 262 −52% 4 03 Jun 2022
Chile 728 38 242 −30% 2 18 Jun 2022
Argentina 265 6 44 −54% 2 03 Jun 2022
Puerto Rico 160 56 23 −50% 2 01 Jul 2022
Bolivia (Plurinational State of) 129 11 26 −40% 3 03 Aug 2022
Ecuador 68 4 9 −40% 6 14 Jun 2022
Dominican Republic 31 3 10 −58% 3 06 Jul 2022
Guatemala 12 1 0 −100% 10 04 Aug 2022
Jamaica 12 4 1 −80% 6 08 Jul 2022
Panama 12 3 0 −100% 13 06 Jul 2022
Uruguay 5 1 0 −100% 12 31 Jul 2022
Costa Rica 4 1 1 0% 4 21 Jul 2022
Honduras 4 0 0 0% 17 04 Aug 2022
Aruba 3 28 1 0% 6 04 Aug 2022
Venezuela (Bolivarian Republic of) 3 0 0 0% 17 14 Jun 2022
Bahamas 2 5 0 0% 17 27 Jun 2022
Cuba 2 0 0 0% 17 04 Aug 2022
El Salvador 2 0 1 0% 6 04 Aug 2022
Guyana 2 2 0 0% 17 04 Aug 2022
Barbados 1 4 0 0% 17 19 Jul 2022
Bermuda 1 16 0 0% 17 23 Jul 2022
Curaçao 1 6 0 0% 5 04 Aug 2022
Guadeloupe 1 2 0 0% 17 04 Aug 2022
Martinique 1 3 0 0% 17 20 Jul 2022
Paraguay 1 0 0 0% 17 04 Aug 2022
Saint Martin 1 26 0 0% 17 04 Aug 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.11 Table - Eastern Mediterranean Region

Summary of Monkeypox cases
As of 19 Sep 2022
Total Cases Total cases per 1M inhabitants Cases in past week1 7-day % change in cases1 Days since last report Date of first reported case
Eastern Mediterranean Region
United Arab Emirates 16 2 0 0% 57 24 May 2022
Lebanon 11 2 0 −100% 10 20 Jun 2022
Saudi Arabia 8 0 0 0% 20 14 Jul 2022
Sudan 6 0 2 −50% 4 01 Aug 2022
Qatar 4 1 1 0% 4 21 Jul 2022
Morocco 3 0 0 0% 21 02 Jun 2022
Bahrain 1 1 1 0% 3 16 Sep 2022
Iran (Islamic Republic of) 1 0 0 0% 32 18 Aug 2022
Jordan 1 0 0 −100% 11 08 Sep 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.12 Table - European Region

Summary of Monkeypox cases
As of 19 Sep 2022
Total Cases Total cases per 1M inhabitants Cases in past week1 7-day % change in cases1 Days since last report Date of first reported case
European Region
Spain 7,037 149 55 −82% 0 18 May 2022
France 3,898 60 113 −55% 0 19 May 2022
Germany 3,563 43 26 −59% 0 20 May 2022
The United Kingdom 3,552 52 68 −51% 0 07 May 2022
Netherlands 1,209 70 14 −62% 0 22 May 2022
Portugal 908 88 10 −73% 0 17 May 2022
Italy 828 14 23 −58% 0 19 May 2022
Belgium 744 65 18 −53% 0 19 May 2022
Switzerland 502 58 14 −36% 0 21 May 2022
Austria 301 34 15 −46% 0 23 May 2022
Israel 247 28 1 −86% 0 21 May 2022
Denmark 183 31 2 −67% 0 23 May 2022
Sweden 179 17 5 −69% 0 18 May 2022
Ireland 173 35 13 −55% 0 16 May 2022
Poland 167 4 11 −58% 0 13 Jun 2022
Norway 89 17 4 −43% 0 31 May 2022
Hungary 75 8 4 −20% 0 31 May 2022
Greece 69 6 3 −73% 0 09 Jun 2022
Czechia 65 6 3 −75% 0 24 May 2022
Luxembourg 55 88 1 −50% 0 16 Jun 2022
Slovenia 46 22 0 −100% 0 24 May 2022
Romania 38 2 0 −100% 0 14 Jun 2022
Finland 33 6 0 −100% 0 20 May 2022
Malta 33 64 0 −100% 0 30 May 2022
Serbia 31 4 0 0% 0 17 Jun 2022
Croatia 27 7 0 0% 0 24 Jun 2022
Slovakia 14 3 0 0% 0 07 Jul 2022
Iceland 12 33 0 0% 0 09 Jun 2022
Estonia 11 8 1 0% 0 28 Jun 2022
Bulgaria 6 1 1 −50% 0 23 Jun 2022
Gibraltar 6 178 0 0% 0 02 Jun 2022
Cyprus 5 6 0 0% 0 03 Aug 2022
Latvia 5 3 1 0% 0 03 Jun 2022
Lithuania 5 2 0 0% 0 04 Aug 2022
Andorra 4 52 0 0% 0 25 Jul 2022
Bosnia and Herzegovina 3 1 0 0% 0 14 Jul 2022
Monaco 3 76 0 0% 0 12 Aug 2022
Georgia 2 0 0 0% 0 15 Jun 2022
Greenland 2 35 0 0% 0 10 Aug 2022
Montenegro 2 3 0 0% 0 31 Jul 2022
Republic of Moldova 2 0 0 0% 0 09 Aug 2022
Russian Federation 2 0 0 −100% 0 12 Jul 2022
Türkiye 1 0 0 0% 0 30 Jun 2022
Ukraine 1 0 1 0% 0 15 Sep 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.13 Table - South-East Asia Region

Summary of Monkeypox cases
As of 19 Sep 2022
Total Cases Total cases per 1M inhabitants Cases in past week1 7-day % change in cases1 Days since last report Date of first reported case
South-East Asia Region
India 12 0 2 0% 3 14 Jul 2022
Thailand 8 0 1 0% 3 21 Jul 2022
Indonesia 1 0 0 0% 3 22 Aug 2022
1 Using most recently complete international standard week (Monday - Sunday)


2.14 Table - Western Pacific Region

Summary of Monkeypox cases
As of 19 Sep 2022
Total Cases Total cases per 1M inhabitants Cases in past week1 7-day % change in cases1 Days since last report Date of first reported case
Western Pacific Region
Australia 132 5 3 −62% 4 20 May 2022
Singapore 19 3 3 0% 4 21 Jun 2022
China2 5 0 1 −50% 3 24 Jun 2022
New Zealand 5 1 0 0% 16 11 Jul 2022
Japan 4 0 0 0% 40 25 Jul 2022
Philippines 4 0 0 0% 28 29 Jul 2022
Republic of Korea 2 0 0 0% 16 22 Jun 2022
Guam 1 6 1 0% 7 12 Sep 2022
New Caledonia 1 4 0 0% 69 12 Jul 2022
1 Using most recently complete international standard week (Monday - Sunday)
2 Cases shown include those in mainland China, Hong Kong SAR and Taipei


2.15 Table - countries with last case reported 21 or more days ago

Days since last reported case
As of 19 Sep 2022
Last Reported Case Days Elapsed
African Region
Benin 15 Jun 2022 96
Cameroon 12 Jul 2022 69
Democratic Republic of the Congo 25 Aug 2022 25
South Africa 29 Aug 2022 21
European Region
Türkiye 30 Jun 2022 81
Andorra 5 Aug 2022 45
Greenland 10 Aug 2022 40
Gibraltar 11 Aug 2022 39
Lithuania 11 Aug 2022 39
Monaco 12 Aug 2022 38
Bosnia and Herzegovina 14 Aug 2022 36
Iceland 16 Aug 2022 34
Georgia 17 Aug 2022 33
Republic of Moldova 17 Aug 2022 33
Serbia 18 Aug 2022 32
Montenegro 22 Aug 2022 28
Cyprus 29 Aug 2022 21
Western Pacific Region
New Caledonia 12 Jul 2022 69
Japan 10 Aug 2022 40
Philippines 22 Aug 2022 28
Region of the Americas
Barbados 19 Jul 2022 62
Martinique 20 Jul 2022 61
Bermuda 23 Jul 2022 58
Saint Martin 4 Aug 2022 46
Guadeloupe 5 Aug 2022 45
Bahamas 20 Aug 2022 30
Curaçao 20 Aug 2022 30
Venezuela (Bolivarian Republic of) 25 Aug 2022 25
Paraguay 26 Aug 2022 24
Eastern Mediterranean Region
United Arab Emirates 24 Jul 2022 57
Iran (Islamic Republic of) 18 Aug 2022 32
Morocco 29 Aug 2022 21
South-East Asia Region
Indonesia 22 Aug 2022 28


2.16 Epidemic curve by country

Epidemic curve shown for cases reported up to 19 Sep 2022 to avoid showing incomplete weeks of data. In general, trends should be interpretted with caution, as the majority of countries do not report cases on a daily basis.

 



  1. Weekly reported cases, and weekly cases shown in the epidemic curve are aggregated according to international standard weeks, running from Monday to Sunday.

3 Detailed case data

Detailed case data are acquired via direct reporting of case based data via WHO Member States. Data from cases are reported1 according to the WHO minimum dataset under the International Health Regulations (IHR 2005) Article 6, and subsequently aggreagated and presented below. Note that completeness of records is variable, meaning denominators for each output may be different from one another. All of the following is derived from the detailed case data, and as a result, overall numbers may not be reflective of figures shown with aggregate case numbers. All detailed cases shown are confirmed cases, where the reporting date occured after 01 January 2022.


  1. Note that a small number of detailed case reports are constructed from official public reports about individual cases.

3.1 Reporting coverage

The detailed case dataset was last updated on September 19 2022. As of this date, the total number of detailed confirmed cases reported is 55,411, representing 91.2% of all aggregated cases reported.

The table below indicate the reporting coverage between reported aggregated confirmed cases and detailed confirmed cases by countries and per region.

Note that for all tables below, in order to best align modes of reporting, total confirmed cases are shown as of:

  1. The most recent Friday (16 September) for data in the Region of the Americas.

  2. The most recent Tuesday (13 September) for data in the European Region.

Total cases shown fully as of 19 September are shown in the global trends section.

3.1.1 Table - Coverage by region

Monkeypox reporting completeness
As of 19 Sep 20221
Total Confirmed Cases Total Detailed Confirmed Cases2 % Detailed Cases reported
Region of the Americas 36,089 31,542 87.4%
European Region 23,837 23,623 99.1%
African Region 587 173 29.5%
Western Pacific Region 173 24 13.9%
Eastern Mediterranean Region 51 40 78.4%
South-East Asia Region 21 9 42.9%
1 Total confirmed cases shown as of date of last detailed case report for the WHO Region of the Americas and WHO European Region.
2 Note that in rare cases total detailed cases may exceed total confirmed cases due to ongoing data cleaning issues




3.3 Case profile (overall)

As shown below, and stated previously, the ongoing outbreak is largely developing in men who have sex with men (defined as homosexual or bisexual males in detailed case forms) networks. In the following analyses, we have re-coded men reported as bisexual as men who have sex with men. Note that reported sexual orientation does not necessarily reflect who the case has had recent sexual history with nor does it imply sexual activity. Generally, severity has been low, with few reported hospitalisations and deaths:

Key features of these cases are as follows:

  • 97.4% (31295/32125) of cases with available data are male, the median age is 35 years (IQR: 30 - 42).

  • Males between 18-44 years old continue to be disproportionately affected by this outbreak as they account for 78.0% of cases.

  • Of all cases with available data, 2.6% (830/32125) are female:

    • The majority of of these cases are reported from the Region of the Americas (422/830; 51%) and the European Region (339/830; 41%)

    • Of the cases where sexual orientation is reported, the majority are Heterosexual (246/288; 85%).

    • The most commonly reported exposure setting is in a household (29/93; 31%), and the most common form of transmission is via sexual encounters (128/192; 67%)

  • Of the 33,363 cases where age was available, there were 293 (0.9%) cases reported aged 0-17, out of which 86 (0.3%) were aged 0-4:

    • The majority of cases aged 0-17 are reported from the Region of the Americas (164 /293; 56%).

    • Of the cases aged 0-17, 0 have reported exposure in a school setting.

  • Among cases with known data on sexual orientation, 90.9% (13940/15339) identified as men who have sex with men. Of those identified as men who have sex with men, 417 / 13940 (3.0%) were identified as bisexual men.

  • Among those with known HIV status 44.2% (7,709/17,444) were HIV-positive. Note that information on HIV status is not available for the majority of cases, and for those for which it is available, it is likely to be skewed towards those reporting positive HIV results.

  • 415 cases were reported to be health workers. However, most were infected in the community and further investigation is ongoing to determine whether the remaining infection was due to occupational exposure.

  • Of all reported types of transmission, a sexual encounter was reported most commonly, with 10,215 of 11,242 (90.9%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 3,099 of 5,280 (58.7%) of all likely exposure categories.

3.3.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. When considering some variables, it is more likely that a yes response will be obtained when compared to a no response after consideration of true proportions of these factors. This is most likely to be true for variables where reported answers can only be yes or no, such as HIV status, health worker status, travel history, hospitalisation, ICU, and death.

Case profiles
As of September 19 2022
Reported values1 Unknown or Missing Value
Yes No
Men who have sex with men 13940 (90.9%) 1399 (9.1%) 40054
HIV-Positive 7706 (44.2%) 9734 (55.8%) 37953
Health worker 415 (3.7%) 10922 (96.3%) 44056
Travel History 1340 (26.6%) 3690 (73.4%) 50363
Sexual Transmission 10211 (87.6%) 1452 (12.4%) 43730
Hospitalised2 1688 (7.0%) 22288 (93.0%) 31417
ICU 18 (0.2%) 8097 (99.8%) 47278
Died 8 (0.0%) 21020 (100.0%) 34365
1 Note given true proportions of variables, yes reporting may be common than no reporting
2 May be hospitalised for isolation or medical treatment




3.3.2 Age-sex pyramid



3.3.3 Age-sex pyramid by region

Note that only regions with 50 or more cases with age and sex information are shown. Note different x-axis scales.



3.3.4 Age-sex pyramid (Hospitalised cases)

Note that some cases represented below may be hospitalised for isolation rather than treatment purposes.



3.3.5 Transmission type

Transmission data were available for 11,667/55,411 (21.1%) of cases.

When considering transmission, note that separating transmission via skin-to-skin contact during sex and transmission via bodily fluids is not possible. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases.



3.3.6 Exposure settings

Exposure setting data were available for 5,897/55,411 (10.6%) of cases.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation here between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.



3.4 Case profile (excluding men who have sex with men)

The following outputs apply to cases that are not men who have sex with men, and sexual orientation is known. Other categories of sexual orientation that are reportable are:

  • Heterosexual
  • Lesbian (women who have sex with women)
  • Other

As stated above, men who have sex with men in this case refers to those who have a reported sexual orientation of men whi have sex with men, and men reported as bisexual. As above, note that reported sexual orientation does not necessarily reflect persons who the case has had recent sexual history with nor does it imply sexual activity. Up until this point in time, the 2022 multi-country Monkeypox outbreak has been overwhelmingly concentrated in networks of men who have sex with men For this reason, understanding events in which individuals of other sexual orientation have acquired monkeypox is important to monitor potential of sustained spillover into the general population.

  • 76.0% (911/1198) of cases with available data are male; the median age is 33 years (IQR: 27-41).

  • Males between 18-44 years old account for 60.5% of cases.

  • Among those with known HIV status 25.8% (279/1082) were HIV-positive. Note that information on HIV status is not available for the majority of cases, and for those for which it is available, it is likely to be skewed towards those reporting positive HIV results.

  • 52 cases were reported to be health workers. However, most were infected in the community and further investigation is ongoing to determine whether the remaining infection was due to occupational exposure.

  • Of all reported types of transmission, sexual encounter was reported most commonly, with 255 of 338 (75.4%) of all reported transmission events.

  • Of all settings in which cases were likely exposed, the most common was in party setting with sexual contacts, with 51 of 166 (30.7%) of all likely exposure categories.

3.4.1 Demographic Information

Note that the proportions shown below should be interpreted with caution. When considering some variables, it is more likely that a yes response will be obtained when compared to a no response after consideration of true proportions of these factors. This is most likely to be true for variables where reported answers can only be yes or no, such as HIV status, health worker status, travel history, hospitalisation, ICU, and death.

Case profiles (excluding men who have sex with men)
As of September 19 2022
Reported values1 Unknown or Missing Value
Yes No
Men who have sex with men 0 1399 (100.0%) 0
HIV-Positive 279 (25.8%) 803 (74.2%) 317
Health worker 52 (5.7%) 858 (94.3%) 489
Travel History 91 (20.7%) 348 (79.3%) 960
Sexual Transmission 255 (62.2%) 155 (37.8%) 989
Hospitalised2 110 (10.2%) 972 (89.8%) 317
ICU 3 (0.8%) 393 (99.2%) 1003
Died 2 (0.2%) 869 (99.8%) 528
1 Note given true proportions of variables, yes reporting may be common than no reporting
2 May be hospitalised for isolation or medical treatment




3.4.2 Age-sex pyramid



3.4.3 Transmission type

Transmission data were available for 410/1,399 (29.3%) of cases.

When considering transmission, note that separating transmission via skin-to-skin contact during sex and transmission via bodily fluids is not possible. While skin-to-skin contact with lesions remains an important transmission route, monkeypox virus has been isolated from semen samples and rectal swabs from confirmed cases.

3.4.4 Exposure settings

Exposure setting data were available for 151/1,399 (10.8%) of cases that were not men who have sex with men.

Note that multiple exposure settings can be attributed to a single case. Here, differentiation here between party settings and large events is determined by size of the event, although there is no formal size threshold to distinguish the two.

3.5 Symptomatology

Although most cases in current outbreaks have presented with mild disease symptoms, monkeypox virus (MPXV) may cause severe disease in certain population groups (young children, pregnant women, immunosuppressed persons)

Among the cases who reported at least one symptom, the most common symptom is any rash and is reported in 85% of cases with at least one reported symptom. Note that identifying true denominators for symptomatology is difficult due to a general lack of negative reporting and symptom definitions that may vary between countries’ reporting systems.

A bar chart and table showing symptoms is shown below. Here any rash refers to one or more rash symptoms (systemic, oral, genital, or unknown location), and any lymphadenopathy refers to either general or local lymphadenopathy.

3.5.1 Bar chart - Symptoms

3.5.2 Table - Symptoms

Summary of symptoms
As of September 19 2022
Number
Any rash 19016 (84.7%)
Fever 12803 (57.1%)
Systemic rash 12047 (53.7%)
Genital rash 9323 (41.6%)
Headache 6754 (30.1%)
Fatigue 6639 (29.6%)
Any lymphadenopathy 6459 (28.8%)
Muscle ache 6072 (27.1%)
General lymphadenopathy 5401 (24.1%)
Local lymphadenopathy 4155 (18.5%)
Rash, unknown location 3176 (14.2%)
Sore throat 2618 (11.7%)
Oral rash 1963 (8.7%)
Chills 1461 (6.5%)
Vomiting 444 (2.0%)
Conjunctivitis 99 (0.4%)
Asymptomatic 16 (0.1%)
Other 4 (0.0%)
Cough 0
Diarrhea 0
Genital oedema 0
Lymphadenopathy, location unknown 0
Anogenital pain and/or bleeding 0

 


4 In focus: West and Central Africa

Since 1970, human cases of monkeypox have been reported in 9 countries in the WHO African region: Cameroon, Central African Republic, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Gabon, Liberia, Nigeria, and Sierra Leone. The true burden of monkeypox in these countries is not known. This section specifically focuses on those countries in the African region with a history of monkeypox, in order to highlight any differences in epidemiology between those countries and those within the ongoing 2022 monkeypox outbreak without a history of monkeypox. Notably, while the ongoing 2022 monkeypox outbreak has been associated with Clade II of monkeypox virus, historically outbreaks have been driven by that and Clade I.

Historically, the sexual component of transmission in the countries above has been thought to contribute less to human to human transmission of monkeypox than has been observed in the ongoing global outbreak. It should also be noted that there is limited testing capacity for monkeypox in many of these countries, which has led to underascertainment of monkeypox cases.

In 2022, as of 19 Sep 2022, there have been 495 confirmed cases of monkeypox reported in these countries and 10 deaths. These represent 1% and 43% of global cases and deaths respectively. In addition, 173 (35% of all cases) detailed cases have been reported to WHO.

Of those cases with detailed data:

  • 110 male cases (64.3%) and 61 female cases (35.7%) have been reported

  • The median age is 25 (IQR: 11 - 35).

  • Of the 168 cases where age was available, there were 65 (38.7% of total) cases reported aged 0-17, out of which 21 (12.5% of total) were aged 0-4.

  • There are currently no detailed cases for which transmission or exposure setting detail is available

Trends from these countries are shown below:

4.1 Epidemic curve by date of notification (cases)

Epidemic curve shown for cases reported up to 19 Sep 2022 to avoid showing incomplete weeks of data.

4.2 Epidemic curve by date of notification (deaths)

Epidemic curve shown for deaths reported up to 19 Sep 2022 to avoid showing incomplete weeks of data.

4.3 Epidemic curve by date of onset

This epidemic curve is shown for those cases with detailed case data, giving date of onset.

4.4 Age-sex pyramid

 


5 Literature Summary & Epidemic Parameters

In order to promote a better understanding of the dynamics of the current monkeypox outbreak and to support forecasting work, WHO has undertaken an effort to extract epidemiological parameters, such as incubation period and generation interval, from the literature. The initial literature screening is performed and maintained by the Public Health Agency of Canada (PHAC). The overall search strategy is as follows:

  • Inclusion criteria: monkeypox and monkeypox virus
  • Study design:
    • Any study design including primary and secondary studies (both animal and human)
    • Guidelines and commentaries are not excluded but are not searched systematically.
  • Publication language: no restriction for peer-reviewed articles, grey literature is focused on English
  • Publication date: from April 14, 2022
  • Bibliographic databases and other sources searched:
    • PubMed Scopus
    • Pre-print servers: Europe PMC, arXiv and SSRN
    • WHO, PHAC, CDC, ECDC, UKHSA

The tables below provide an overview of the most relevant estimates for incubation period and generation interval extracted from the literature where the following criteria are met:

  • Studies with a sample size greater than 5
  • Clear estimate of the specific parameter

The epidemic parameter tables are updated once per week on Fridays. Please note that some of these sources are still undergoing the peer-review process, therefore readers are advised to exercise care when interpreting findings.

5.1 Parameters

Incubation Period
As of 12 Sep 2022
Reference N Mean1 95% CI 95% CrI SD1 Median1 Range min1 Range max1 Distribution
lower1 upper1 lower1 upper1
Miura et al. [1] 18 8.5 - - 6.6 10.9 - - - - Log-normal
Charniga et al. [2] 40 7.6 - - 6.2 9.7 1.8 6.4 - - Log-normal
Rodríguez et al. [3] 45 - - - - - - - - - -
Thornhill et al. [4] 23 - - - - - - 7.0 3 20 -
Català et al. [5] 77 - - - - - - 6.0 4 9 -
Tarín-Vicente et al. [6] 144 - - - - - - 7.0 1 19 -
Guzzetta et al. [7] 30 9.1 6.5 10.9 - - - - - - Gamma
Mailhe et al. [8] 246 6.0 - - - - - - - - -
Moschese et al. [9] 32 11.0 - - - - - - - - -
Source: PHAC
1 Units are in days




Generation Interval
As of 12 Sep 2022
Reference N Mean1 95% CrI low1 95% CrI high1 SD1 Distribution
Guzzetta et al. [7] 16 12.5 7.5 17.3 - Gamma
Source: PHAC
1 Units are in days



5.2 Bibliography

  1. Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022 ( 1150) Euro Surveill . Miura, F., van Ewijk, C. E., Backer, J. A., Xiridou, M., Franz, E., Op de Coul, E., Brandwagt, D., van Cleef, B., van Rijckevorsel, G., Swaan, C., van den Hof, S., Wallinga, J.. 27,2022/06/18 (2022): #pages#–> 10.2807/1560-7917.Es.2022.27.24.2200448 ; #URL#

  2. Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak ( 722) medRxiv . Charniga, Kelly, Masters, Nina B., Slayton, Rachel B., Gosdin, Lucas, Minhaj, Faisal S., Philpott, David, Smith, Dallas, Gearhart, Shannon, Alvarado-Ramy, Francisco, Brown, Clive, Waltenburg, Michelle A., Hughes, Christine M., Nakazawa, Yoshinori. #volume# (2022): 2022.06.22.22276713–> 10.1101/2022.06.22.22276713 ; http://medrxiv.org/content/early/2022/06/23/2022.06.22.22276713.abstract

  3. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022 ( 888) Emerg Infect Dis . Rodríguez, B. S., Herrador, B. R. G., Franco, A. D., Fariñas, M. P. S., Del Amo Valero, J., Llorente, A. H. A., de Agreda, Jpap, Malonda, R. C., Castrillejo, D., Chirlaque López, M. D., Chong, E. J., Balbuena, S. F., García, V. G., García-Cenoz, M., Hernández, L. G., Montalbán, E. G., Carril, F. G., Cortijo, T. G., Bueno, S. J., Sánchez, A. L., Linares Dópido, J. A., Lorusso, N., Martins, M. M., Martínez Ochoa, E. M., Mateo, A. M., Peña, J. M., Antón, A. I. N., Otero Barrós, M. T., Martinez, Mdcp, Jiménez, P. P., Martín, O. P., Rivas Pérez, A. I., García, M. S., Soria, F. S., Sierra Moros, M. J.. 28,2022/07/13 (2022): #pages#–> 10.3201/eid2809.221051 ; https://wwwnc.cdc.gov/eid/article/28/9/22-1051_article

  4. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 ( 933) N Engl J Med . Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., Palich, R., Nori, A., Reeves, I., Habibi, M. S., Apea, V., Boesecke, C., Vandekerckhove, L., Yakubovsky, M., Sendagorta, E., Blanco, J. L., Florence, E., Moschese, D., Maltez, F. M., Goorhuis, A., Pourcher, V., Migaud, P., Noe, S., Pintado, C., Maggi, F., Hansen, A. E., Hoffmann, C., Lezama, J. I., Mussini, C., Cattelan, A., Makofane, K., Tan, D., Nozza, S., Nemeth, J., Klein, M. B., Orkin, C. M.. 2022/07/23 (2022): #pages#–> 10.1056/NEJMoa2207323 ; #URL#

  5. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases ( 1008) Br J Dermatol . Català, A., Clavo Escribano, P., Riera, J., Martín-Ezquerra, G., Fernandez-Gonzalez, P., Revelles Peñas, L., Simón Gozalbo, A., Rodríguez-Cuadrado, F. J., Guilera Castells, V., De la Torre Gomar, F. J., Comunión Artieda, A., Fuertes de Vega, L., Blanco, J. L., Puig, S., García Miñarro Á, M., Fiz Benito, E., Muñoz-Santos, C., Repiso-Jiménez, J. B., Ceballos-Rodriguez, C., García Rodríguez, V., Castaño Fernández, J. L., Sánchez-Gutiérrez, I., Calvo López, R., Berna-Rico, E., de Nicolás-Ruanes, B., Corella Vicente, F., Tarín Vicente, E. J., Fernández de la Fuente, L., Riera-Martí, N., Descalzo-Gallego, M., Grau-Perez, M., García-Doval, I., Fuertes, I.. 2022/08/03 (2022): #pages#–> 10.1111/bjd.21790 ; #URL#

  6. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study ( 1074) Lancet . Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., Arando, M., Arroyo-Andrés, J., Calderón-Lozano, L., Casañ, C., Cabrera, J. M., Coll, P., Descalzo, V., Folgueira, M. D., García-Pérez, J. N., Gil-Cruz, E., González-Rodríguez, B., Gutiérrez-Collar, C., Hernández-Rodríguez, Á., López-Roa, P., de Los Ángeles Meléndez, M., Montero-Menárguez, J., Muñoz-Gallego, I., Palencia-Pérez, S. I., Paredes, R., Pérez-Rivilla, A., Piñana, M., Prat, N., Ramirez, A., Rivero, Á., Rubio-Muñiz, C. A., Vall, M., Acosta-Velásquez, K. S., Wang, A., Galván-Casas, C., Marks, M., Ortiz-Romero, P., Mitjà, O.. 2022/08/12 (2022): #pages#–> 10.1016/s0140-6736(22)01436-2 ; #URL#

  7. Early Estimates of Monkeypox Incubation Period, Generation Time, and Reproduction Number, Italy, May-June 2022 ( 1189) Emerg Infect Dis . Guzzetta, G., Mammone, A., Ferraro, F., Caraglia, A., Rapiti, A., Marziano, V., Poletti, P., Cereda, D., Vairo, F., Mattei, G., Maraglino, F., Rezza, G., Merler, S.. 28,2022/08/23 (2022): #pages#–> 10.3201/eid2810.221126 ; https://wwwnc.cdc.gov/eid/article/28/10/22-1126_article

  8. Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: an observational cohort study ( 1238) Clin Microbiol Infect . Mailhe, M., Beaumont, A. L., Thy, M., Le Pluart, D., Perrineau, S., Houhou-Fidouh, N., Deconinck, L., Bertin, C., Ferré, V. M., Cortier, M., C.,De La Porte Des Vaux,, Phung, B. C., Mollo, B., Cresta, M., Bouscarat, F., Choquet, C., Descamps, D., Ghosn, J., Lescure, F. X., Yazdanpanah, Y., Joly, V., Peiffer-Smadja, N.. 2022/08/27 (2022): #pages#–> 10.1016/j.cmi.2022.08.012 ; #URL#

  9. Natural history of Human Monkeypox in individuals attending a sexual health clinic in Milan, Italy ( 1262) J Infect . Moschese, D., Pozza, G., Giacomelli, A., Mileto, D., Cossu, M. V., Beltrami, M., Rizzo, A., Gismondo, M. R., Rizzardini, G., Antinori, S.. 2022/08/26 (2022): #pages#–> 10.1016/j.jinf.2022.08.019 ; #URL#

 


6 Disclaimers

6.1 Data Overview and Visualizations

The WHO 2022 monkeypox global trends report aims to provide frequently updated data visualizations. Caution must be taken when interpreting all data presented, and differences between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times are to be expected. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. All counts are subject to variations in case detection, definitions, laboratory testing, and reporting strategies between countries, states and territories.

WHO makes no warranties or representations regarding the contents, appearance, completeness, technical specifications, or accuracy of the report. WHO disclaims all responsibility relating to, and shall not be liable for, any use of the report, the results of such use, or the reliance thereon.

WHO reserves the right to make updates and changes to the report without notice, and accepts no liability for any errors or omissions in this regard.

The user of the report is responsible for the interpretation and use of the analysis and outputs performed by the report. The submission of content to the report does not imply WHO’s approval or endorsement of that content, or that the content is appropriate for any purpose or meets any established standard or requirement

Any designations employed or presentation by the user in its use of the app, including tables and maps, do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries.

All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas).

7 Acknowledgements

We gratefully acknowledge the input of national public health staff involved in surveillance activities and data submission to WHO, the European Centre for Disease Prevention and Control (ECDC) for the provision of surveillance data collected via the TESSy platform, as well as external partners who contributed additional insights and contextual information on the data.